The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and –independent mechanisms by Tatiana Pazina, Ashley M. James, Alexander W. MacFarlane, Natalie A. Bezman, Karla A. Henning, Christine Bee, Robert F. Graziano, Michael D. Robbins, Adam D. Cohen, Kerry S. Campbell

Get full text

821 The combination of a trastuzumab ISAC and pertuzumab augments anti-tumor efficacy in multiple HER2+ tumor models relative to trastuzumab plus pertuzumab by Edith A Perez, Andrew Luo, Anthony Lucas, Han K Kim, Paul D Ponath, Katelynn A McEachin, Karla A Henning, Shelley E Ackerman, Steven J Chapin, Michael N Alonso, Cecelia I Pearson, David Omstead

1147-D Preclinical characterization of a novel claudin 18.2 targeting-ISAC with robust potency and acceptable safety profile by Matthew Zhou, William Mallet, Romas Kudirka, Han K Kim, Justin Monnier, Chi-Ling Fu, Jennifer E Melrose, Hung Dao, Paul D Ponath, Katelynn A McEachin, David T Omstead, Cindy Kreder, Stefan Chun, Ying Yueh Lee, Rachel Grgich, Tracey J Lin, Joshua A Walker, Karla A Henning, Shelley E Ackerman, Diane Carrera, Steven J Chapin, Dowdy Jackson, Changshou Gao, Michael N Alonso